AMGN — AMGEN INC catalysts
Next verified catalyst
2026-11-30 — A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 10 · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MT
Phase 1/2 · Advanced MTAP-null Solid Tumors |
AMGN AMGEN INC | Anvumetostat, Docetaxel, Comparator Anvu |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-14 in 1mo
ESTIMATED |
READOUT
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
Phase 3 · Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) |
AMGN AMGEN INC | ABP 234, Pembrolizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2027-01-06 in 2mo
ESTIMATED |
READOUT
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Dis
Phase 1/2 · Thyroid Eye Disease |
AMGN AMGEN INC | AMG 732 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2027-01-21 in 3mo
ESTIMATED |
READOUT
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabe
Phase 3 · Obesity |
AMGN AMGEN INC | Maridebart Cafraglutide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2027-01-21 in 3mo
ESTIMATED |
READOUT
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2
Phase 3 · Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight |
AMGN AMGEN INC | Maridebart cafraglutide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|